# EDGAR Filing Document

**Accession Number:** 0001442836
**File Stem:** 0001104659-25-059380
**Filing Date:** 2025-6
**Character Count:** 8121
**Document Hash:** 45cc726cf90e9fcbe301fd894ab39abf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-059380.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001104659-25-059380

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250612

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mersana Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001442836
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38129
- **FILM NUMBER:** 251046905

**BUSINESS ADDRESS:**
- **STREET 1:** 840 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-498-0020

**MAIL ADDRESS:**
- **STREET 1:** 840 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MERSANA THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080813

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 12, 2025**

**MERSANA THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38129** | **04-3562403** |
| **(State or other jurisdiction <br> of incorporation)** | **(Commission**<br> **File Number)**  | **(IRS Employer**<br> **Identification No.)**  |

---

---

| | |
|:---|:---|
| **840 Memorial Drive** **<br> Cambridge**, Massachusetts** | **02139** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

Registrant's telephone number, including area code: **(617) 498-0020**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

◻&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| Common Stock, $0.0001 par value | MRSN | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On June 12, 2025, Mersana Therapeutics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following four proposals: (1) to elect three Class II directors to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified ("Proposal 1"), (2) to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement on Schedule 14A filed by the Company with the U.S. Securities and Exchange Commission on April 29, 2025 ("Proposal 2"), (3) to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 ("Proposal 3"), and (4) to approve an amendment to the Company's Fifth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's issued shares of common stock at a ratio within the range of not less than 1-for-2 and not greater than 1-for-25, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of the Company's Board of Directors, without further approval or authorization of the Company's stockholders ("Proposal 4" or the "Reverse Stock Split Proposal"). The final results of the voting on each proposal are set forth below.

**Proposal 1 - Election of Directors**

The Company's stockholders elected the three persons listed below as Class II directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Nominees** | **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
| Allene M. Diaz |  | 63634144 |  | 1190888 |  | 29986 |  | 21366700 |
| Andrew A. F. Hack, M.D., Ph.D. |  | 63779513 |  | 1058769 |  | 16736 |  | 21366700 |
| Kristen M. Hege, M.D. |  | 49598858 |  | 15237596 |  | 18564 |  | 21366700 |

---

**Proposal 2 –** **Advisory Vote on Executive Compensation**

The Company's stockholders approved Proposal 2. The votes cast were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 63571120 |  | 1136066 |  | 147832 |  | 21366700 |

---

**Proposal 3 – Ratification of Selection of Independent Registered Public Accounting Firm**

The Company's stockholders approved Proposal 3. The votes cast were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** |
|  | 85866981 |  | 337691 |  | 17046 |

---

**Proposal 4 –** **Reverse Stock Split Proposal**

The Company's stockholders approved Proposal 4. The votes cast were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** |
|  | 83480640 |  | 2489457 |  | 251621 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MERSANA THERAPEUTICS, INC.** | **MERSANA THERAPEUTICS, INC.** |
| Date: June 13, 2025 | By: | /s/ Alejandra Carvajal |
|  |  | Alejandra Carvajal |
|  |  | Senior Vice President, Chief Legal Officer and Secretary |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MERSANA THERAPEUTICS, INC.** | **MERSANA THERAPEUTICS, INC.** |
| Date: June 13, 2025 | By: | /s/ Brian DeSchuytner |
|  |  | Brian DeSchuytner |
|  |  | Senior Vice President, Chief Financial Officer |

---